论文部分内容阅读
目的观察罗格列酮辅助治疗对肺纤维化患者的临床效果。方法筛选2013—2014年期间已确诊的肺纤维化患者60例,随机分为两组,A组为罗格列酮治疗组,在常规治疗的基础上口服罗格列酮;B组为常规治疗组。观察患者症状改善情况、胸部影像学、动脉血气和肺功能等。结果治疗后,A组总有效率为53.33%,B组总有效率为43.33%,两组差异有统计学意义(P<0.05);两组的临床症状积分,TCL、FVC和DLCO等肺功能指标,Pa CO2、Pa O2等动脉血气指标均优于治疗前,差异均有统计学意义(P<0.05);且治疗后A组各项指标均优于B组,差异有统计学意义(P<0.05)。结论罗格列酮辅助治疗可以改善患者的临床症状、肺功能和血气情况,提高患者的生活质量。
Objective To observe the clinical effect of rosiglitazone adjuvant therapy on patients with pulmonary fibrosis. Methods Sixty patients with confirmed pulmonary fibrosis between 2013 and 2014 were randomly divided into two groups. Group A was rosiglitazone-treated group, and rosiglitazone was given on the basis of routine treatment. Group B was routinely treated group. To observe the patient’s symptoms, chest imaging, arterial blood gas and lung function. Results After treatment, the total effective rate in group A was 53.33%, the total effective rate in group B was 43.33%, the difference between the two groups was statistically significant (P <0.05). The clinical symptom scores, TCL, FVC and Dlco Indicators, PaCO 2, Pa O 2 and other arterial blood gas indexes were better than before treatment, the differences were statistically significant (P <0.05); and after treatment, the indicators in group A were better than those in group B, the difference was statistically significant (P <0.05). Conclusions Rosiglitazone adjuvant therapy can improve clinical symptoms, pulmonary function and blood gas condition, and improve the quality of life of patients.